Printer Friendly

Dietary polyphenol quercetin protects rat hearts during reperfusion: enhanced antioxidant capacity with chronic treatment / Izole sican kalplerine uygulanan iskemi/reperfuzyon hasarinda quercetinin koruyucu etkisi: kronik kullanimda artmis antioksidan etkinligi.


Objective: Quercetin is an important member of dietary flavonoid family and widely present in red wine and Mediterranean diet. The major objective of the this study is to evaluate the beneficial effects of quercetin in protecting the myocardium from the deleterious effects of ischemia reperfusion (I/R) injury in chronic quercetin treatment with or without an acute quercetin infusion protocols.

Methods: Forty male Sprague-Dawley rats were included in this experimental randomized study/ Langendorff perfused isolated rat hearts were subjected to 60-min of global ischemia period following 60-min of reperfusion. All animals were randomly divided into 4 groups. Group 1 animals were kept as controls. Group 3 and 4 animals received 50 mg/kg quercetin via an intragastric tube for 7 days for chronic treatment. Group 2 and 4 animals received an acute 15 [micro]mol/L infusion for 30 minutes before the onset of ischemia. The myocardial postischemic recovery was compared using hemodynamic data (peak systolic pressure, end-diastolic pressure and +dP/dtmax), coronary flow, biochemical parameters (lactate dehydrogenase, creatine kinase -MB fraction, cardiac troponin I) from coronary effluent, and oxidative stress markers (malondialdehyde, glutathione, glutathione reductase and nitrite) from heart tissue homogenates in each group.

Results: Quercetin has provided increased preservation in myocardial recovery in both chronic and acute treatment protocols compared to non-treated group. According to all estimated hemodynamic parameters, while the statistical difference between acute treated hearts and control hearts was significant (p<0.05); this significance was more clear in chronic treated groups (group III and IV) when compared to control (p<0.01). Likewise, biochemical and oxidative stress markers displayed significant differences in acute treated and chronic treated hearts when compared to control (p<0.05 and p<0.01, respectively).

Conclusion: As a major dietary flavonoid, due to its antioxidant and cytoprotective actions, quercetin has the capacity to protect the myocardial tissue against global ischemia and reperfusion injury. In instances where the molecule is administered for the purpose of acute therapy, this cardioprotective effect of a significant degree can be observed to; however, this potency is further accentuated upon administration as a chronic treatment protocol for seven days. (Anadolu Kardiyol Derg 2007; 7: 404-10)

Key words: Quercetin, heart, ischemia/reperfusion, protection, oxidative stress, antioxidant


Amac: Quercetin Akdeniz diyetinde bol miktarda bulunan polifenol yapida bir maddedir ve guclu bir antioksidandir. Bu calismanin amaci sican kalplerine kronik tedavi ve akut infuzyon olarak verilen quercetinin iskemi-reperfuzyon hasarina karsi koruyucu etkinligini saptamaktir.

Yontemler: Bu deneysel randomize calismaya kirk adet erkek Sprague-Dawley sican dahil edildi. Izole kalpler Langendorff sistemine asilarak Krebbs-Henseleit solusyonu ile perfuze edildi. Kalpler 60 dakika global iskemiyi takiben 60 dakika reperfuzyon uygulandi. Sicanlar rasgele 4 gruba ayrildi. Grup 1 kalpler kontrol grubu olarak kabul edildi. Grup 3 ve grup 4'deki sicanlara deney oncesi bir hafta boyunca 50 mgr/kg oral quercetin verildi. Grup 2 ve grup 4 kalplere deney esnasinda 30 dakika boyunca 15 [micro]mol/lt quercetin infuzyonu uygulandi. Hemodinamik veriler (sistolik basinc, diyastol sonu basinc, dP/dt ve koroner akim miktarlari), koroner akim orneklerinden laktat dehidrogenaz, kreatin kinaz-MB, kardiyak troponin I ve miyokardiyal doku orneklerinde oksidatif stres belirleyicileri (malondialdehid, glutatyon, glutatyon reduktase ve nitrit) calisildi.

Bulgular: Quercetin uygulanan gruplarda reperfuzyon periyodunun her fazinda hemodinamik veriler ve biyokimyasal parametreler kontrol grubuna gore belirgin olarak daha iyi miyokardiyal iyilesmeyi isaret etmistir. Hemodinamik veriler incelendiginde, akut tedavi edilen kalpler ile kontrol grubu arasindaki fark istatistiksel olarak anlamli iken (p<0.05), kronik tedavi edilen grup 3 ve 4 kalplerde kontrol grubuna kiyasla izlenen hemodinamik iyilesme belirgin olarak daha iyi idi (p<0.01). Benzer sekilde olculen biyokimyasal parametreler ve oksidatif stres belirleyicileri hem akut, hem de kronik tedavi edilen kalplerde kontrol grubuna gore anlamli olarak daha iyi idi (p<0.05 ve p<0.01, sirasiyla).

Sonuc: Quercetin, antioksidan etkinligi ile oksidatif strese bagli doku hasarini azaltarak global iskemi sonrasi reperfuzyonda miyokardiyal iyilesmeyi artirmaktadir. Bu koruyucu etki ozellikle kronik tedavi uygulanan kalplerde belirgin olarak izlenmektedir. (Anadolu Kardiyol Derg 2007; 7: 404-10)

Anahtar kelimeler: Quercetin, kalp, iskemi/reperfuzyon, koruma, oksidatif stres, antioksidan


Flavonoids are a big group naturally occurring polyphenolic compounds, which are widely presented in fruits and vegetables, and in particular in grapes. In addition to their broad scale of biological effects, they have been reported to possess antioxidant effects as free radical scavengers, hydrogen-donating compounds, singlet oxygen quenchers, and metal ion chelators (1). Quercetin, (3,5,7,3',4'-pentahydroxy flavone) is an important member of flavonoid family, and it daily intake with dietary that is estimated to be up to 16 mg, in particular in Mediterranean diet (2, 3). It has been reported that quercetin inhibited thrombocyte aggregation (4) and had an anti-hypertensive effect through vasodilator action on vascular smooth muscles (5). The studies that were focused on antioxidant efficiency of flavonoids against ischemia/reperfusion (I/R) injury have demonstrated that, quercetin possesses robust protective effects in renal, cerebral and hepatic I/R models (6-8). Quercetin was also demonstrated to improve contractile function of the left ventricle in experimental myocardial infarction with subsequent 24-hour reperfusion (9). However, studies reporting the effects of this compound against global myocardial I/R injury are scanty.

This study was conducted with the aim of investigating the cardioprotective effects of quercetin against global ischemia and reperfusion injury in rat hearts, and comparison of this efficiency in the chronic treatment with and without an acute infusion protocols.



This study was approved by The Osmangazi University Institutional local animal care and use committee. Male Sprague-Dawley rats, 250-300 g body weight (BW) were used for this study. Animals were fed with a standard rat feed and allowed to drink water ad libitum. Animals were deprived of food for 12 h before the experiments. They were housed in temperature controlled (20-25[degrees] C) cages with a 12-h dark and 12-h light cycles. All procedures were performed in sterilized conditions.


Quercetin was purchased from Sigma, St. Louis, MO, USA, and dissolved in ethanol and then both diluted with tap water to a concentration of 15 mg/ml for oral administration, and diluted with physiological saline to achieve an infusion concentration of 15 [micro]mol/L. Final ethanol concentration in both oral and infusion quercetin cocktails was 0.2 % (vol/vol) (10).

Isolated Heart Preparation

All rats were heparinized (300 IU/kg BW) via femoral vein and anaesthetized with 50 mg/kg BW of sodium pentobarbital administered by intraperitoneal injection. Rat hearts were rapidly excised through a median sternotomy, and immersed into ice-cold heparinized saline solution during preparation, and then mounted on the stainless steel cannula of the modified Langendorff perfusion apparatus via aorta. Aortic perfusion was initiated at a constant perfusion pressure of 80 mm Hg with gassed (95% [O.sub.2], 5% C[O.sub.2]) Krebs-Henseleit bicarbonate buffer (K-H) (in mmol/L: NaCl 118; KCl 4.7; Ca[Cl.sub.2] 2.0; MgS[O.sub.4] 1.2; NaHC[O.sub.3] 25; K[H.sub.2]P[O.sub.4] 1.2; Glucose 11.1) while the pH was at maintained 7.4 to 7.5. A pulmonary arteriotomy was performed to allow free drainage of coronary sinus effluent. The heart temperature was monitored using a thermistor probe placed in the right ventricle wall, and kept constant at 37 [degrees]C during the stabilization, ischemia and reperfusion periods. The right atrium was removed, and the hearts were paced to 300 beats/minute at 4 volts using an external pacemaker (HSE Stimulator P, Type 201, Hugo Sachs Electronic, Germany). A water filled latex balloon was inserted in the left ventricle cavity through a small incision in the left atrium, and connected to a pressure transducer (Transpac II, Abbott, Bedford, MA) by rigid polyethylene tubing. The balloon volume was adjusted to produce a 10 mm Hg of diastolic pressure. Hemodynamic data from the latex balloon were analyzed using a real time data acquisition and analysis system (BIOPACK MP 30 system, Santa Barbara, CA) and displayed on a monitor during the experiment. The hearts were excluded from the experiment if they displayed lower contractile function (+dP/dtmax values below 3000) or severe arrhythmia.

Experimental Design

Forty rats were randomly divided into four groups (Fig. 1):

Group 1 (n=10): These rats were reserved as control group and received 0.2 % (vol/vol) ethanol in tap water via an intra-gastric tube once daily for seven days and saline infusion containing 0.2% (vol/vol) ethanol for 30 minutes after stabilization period during the experiment. Animals in this group were not subjected to quercetin treatment.

Group 2 (n=10): Acute treatment group. These rats were received tap water containing 0.2 % (vol/vol) ethanol via an intra-gastric tube for seven days. Hearts were then subjected to 15 [micro]mol/L quercetin infusion for 30 minutes after stabilization period during the experiment.

Group 3 (n=10): Chronic treatment group. Rats were subjected to 50 mg/kg BW quercetin treatment via an intra-gastric tube once daily for seven days. Hearts in this group were received saline infusion containing 0.2 % (vol/vol) ethanol for 30-minute after stabilization period during the experiment.

Group 4 (n=10): Chronic and acute treatment group. These rats were pretreated with 50 mg/kg BW quercetin via an intra-gastric tube once daily for seven days and received 15 [micro]mol/L quercetin infusion for 30-minute after stabilization period during the experiment.


Since the chronic quercetin and ethanol exposure did not lead to any deleterious effects in the rats, 24 hours after this treatment, the hearts were perfused on Langendorff apparatus. All hearts underwent a 20-min of stabilization period. Then, following the 30-min of infusion period, all hearts in each group were then arrested with crystalloid cardioplegia solution (Plegisol, Abbott, USA) and subjected to 60-minute of global ischemia. Pacing was stopped during ischemia. Following the ischemic period, the hearts were then reperfused for a 60-minute period with K-H solution at 37 [degrees]C and paced at 300 beats/minute.

Hemodynamic Measurements

Left ventricular pressure waveforms (obtained from left ventricular latex balloons) were analyzed, and peak systolic pressure (PSP), end-diastolic pressure (EDP), and the maximum rate of increase and decrease of left ventricular pressure (+dP/dtmax) were recorded at the end of the stabilization period and at 20-minute intervals throughout the reperfusion period. Coronary effluent was collected in a reservoir for one minute and measured as coronary flow (CF) after the stabilization period and at 20-min intervals during reperfusion.

Biochemical Assay

The coronary effluent was collected throughout the stabilization and reperfusion periods separately, and samples were stored at -80 [degrees]C. Ischemic damage was assessed using lactate dehydrogenase (LDH) level (11), creatine kinase (CK-MB) activity (12), troponin I (cTnI) level (13). The LDH and CK-MB activities were determined in Hitachi 917 automated analyzer by using commercial kits supplied from Roche Diagnostic (Mannheim, Germany). Troponin I levels were measured in ACS: 180 automated chemiluminescence system using commercial kits supplied from Bayer Diagnostics (Cedex, France).

Evidence of oxidative stress was determined from heart tissue homogenates using glutathione (GSH), malondialdehyde (MDA), and glutathione reductase (GR) content analysis. Following reperfusion period, at the end of the experiment, the hearts were rapidly arrested by immersing in ice-cold K-H solution, and stored at -80 [degrees]C. The tissues were homogenized in 0.1 M phosphate-buffer (pH 7.4) with Ultra Turrax homogenizer (IKA T18 basic, Wilmington NC, USA). The homogenates were centrifuged 5000 rpm at +4 [degrees]C for 10 min, and the supernatants were removed, and assayed for MDA, GSH and GSSGR levels. Levels of GSH (14), MDA (15) and GR content (16) were measured by the methods referenced.

Tissue nitric oxide levels were correlated with nitrite determination from myocardial homogenates. Nitrite level was determined by using diazotization method. This method depends on diazotization of nitrite with an aromatic amine (sulphonamide) and formation of colorful azo derivative with N-(1-Naftil) etilendiamine (NEDD) (Griess reaction). Then it was measured on spectrophotometrically at 545-555 nm wave length (17).

Statistical Analysis

Results were expressed as means [+ or -] S.E.M. Statistical analysis was performed using ANOVA (variance analysis for multiple comparisons). The normality of data for each group was analyzed using Shapiro-Wilk test. The post hoc Tukey multiple range test was used after ANOVA analysis and p<0.05 was accepted as considering statistical significance.


Hemodynamic recovery (Table 1)

In the present study, quercetin infusion did not modify contractile function in each group. No significant difference was observed in hemodynamic parameters during stabilization and quercetin infusion periods (p>0.05).

Peak systolic pressure: The PSP values obtained from chronic pretreated groups (group 3 and 4) did not differ significantlu at any time during reperfusion (p>0.05). However, group 1 (control) and group 2 (acute treatment group) PSP values were significantly lower than that of groups 3 (chronic treatment group) and 4 (acute and chronic treatment group) (p<0.01 and p<0.05, respectively). Additionally, acute treated hearts in group 2 exhibited statistically higher PSP values than non-treated hearts in group 1 (p<0.05) (Fig. 2).

End-diastolic pressure: According to ANOVA test, no significant difference was observed between group 3 and group 4 hearts during reperfusion (p>0.05). The EDP values obtained from group 2 hearts were significantly higher than in chronic pretreated (groups 3 and 4) hearts throughout reperfusion (p<0.05). However, statistical significance was more evident in group 1 control hearts compared with groups 3 and 4 (p<0.01) throughout reperfusion period. Likewise, EDP values from group 2 were also statistically lower compared to group 1 during all phases of reperfusion period (p<0.05) (Fig. 2).

+dP/dtmax: The chronic pretreated groups (groups 3 and 4) have demonstrated significantly higher +dP/dtmax values at every time points of reperfusion period compared to group 2 (p<0.05) and group 1 (p<0.01) hearts. Acute treated hearts (group 2) exhibited significantly higher +dP/dtmax values than that non-treated hearts (group 1) during all phases of reperfusion (p<0.05) No significant difference was observed between group 3 and 4 throughout reperfusion period (p>0.05) (Fig. 3).


Coronary flow: No significant difference was observed between groups 3 and 4 during reperfusion (p>0.05). Coronary flow values of groups 3 and 4 were significantly higher than of both acute treated group 2 (p<0.05) and non-treated group 1 (p<0.01) at 20th, 40th and 60th minutes of of reperfusion. It was also significantly higher in group 2 compared to group 1 throughout reperfusion (p<0.05) (Fig. 3).

Biochemical results (Table 2)

There were no significant differences in any measured biochemical parameters among the all groups following stabilization period (p>0.05). No significant enzymatic difference was observed between chronic pretreated groups 3 and 4 during reperfusion (p>0.05). However, LDH, CK-MB and cTnI levels from chronic pretreated groups were significantly lower than in both acute treated (group 2) and non-treated (group 1) groups during reperfusion period (p<0.05 and p<0.01, respectively). Significantly less biochemical damage was also determined in group 2 compared to group I throughout reperfusion (p<0.05) (Fig. 4).

Oxidative stress indicators

The MDA levels obtained from groups 3 and 4 were significantly lower than in groups 2 (p<0.05) and 1 (p<0.01) during reperfusion. Likewise, GSH and GR levels were significantly higher in pretreated groups 3 and 4 than in groups 2 and 1 (p<0.05 and p<0.01, respectively). No significant differences were observed in determined markers between groups 3 and 4 (p>0.05). Markers obtained from group 2 hearts were signaled a significantly more potent antioxidant effect than in group 1 hearts (p<0.05) (Fig. 5).


Nitrite levels in group 1 were significantly lower than those in group 2, 3 and 4 (p<0.01). Likewise, determined nitrite levels from myocardial homogenates of group 2 were significantly lower than in groups 3 and 4 levels (p<0.01). Nitrite levels from groups 3 and 4 were similar (p>0.05) (Fig. 5).


In this study, we demonstrated that natural flavonoid quercetin that is found in abundance in the daily diet could protect the heart against global I/R injury and that this effect was more significant in the chronic treatment protocols. The I/R complex is a multidimensional process leading the generation of reactive oxygen species (ROS) and oxidative stress, which results in severe tissue damage (18). Under normal conditions, ROS, which are generated during cellular functions, are eliminated by intrinsic antioxidant enzyme systems like superoxide dismutase (SOD), glutathione peroxidase, and catalase (18). Especially during the early stages of reperfusion, tissue concentrations of ROS increase partly due to increased production and partly due to insufficient levels of antioxidant systems (19). In the myocardial tissue, with the initiation of such a process, increasing amounts of ROS result in I/R damage (20) and finally lead to myocardial injury (21). Reactive oxygen species scavenging agents and antioxidant molecules have the capacity to partially reduce or eliminate deleterious effects induced by I/R injury (22).


Being an important member of the flavonoid family, quercetin is an antioxidant molecule found in fruits and vegetables, mainly in grapes and red wine. The example is the so-called French paradox; despite the consumption of fat rich diet and heavy smoking habits, people living in southern parts of France are identified to have low levels of coronary heart disease and this was related to frequent consumption of wine and Mediterranean diet containing quercetin and similar antioxidant flavonoids (5). Appreciation of ischemia reducing effects of quercetin brought together several studies demonstrating its protective capacity against I/R injury in several different tissues (6-8). Quercetin that was subsequently administered as chronic treatment decreased the myocardial damage by preserving mitochondrial functions in a global ischemia and reperfusion model (23). In our study, quercetin was used as chronic treatment with and without an acute infusion; in addition to investigating the cardioprotective effects of the compound, we aimed at delineating the differences in the efficacies of chronic and acute treatment protocols. Previous study (6), have also reported the efficacy of quercetin in prevention of I/R injury.


Quercetin exerts its antioxidant effects by scavenging free O2 and OH radicals on one hand and by inhibiting xanthine oxidase activity and lipid peroxidation on the other (24). In the study we present, the levels of MDA, which is an indicator of the damage induced by free radicals on lipid tissue were found to be lower in the quercetin groups compared to control group. In a similar manner, levels of GSH and glutathione reductase that were defense mechanisms against ROS damage were found to be higher in quercetin groups, which indicates that quercetin treatment decreases oxidative stress through its antioxidant properties. Thus, lower levels of ischemic enzymes as well as better hemodynamic performance in quercetin administered groups indicate that I/R injury is of lesser level in these hearts. Furthermore, strong cardioprotective effects obtained by quercetin might be due to preconditioning like effects in addition to antioxidant properties. Earlier, it was demonstrated that quercetin increases the secretion of adenosine, which is an important mediator of preconditioning mechanism (25). Besides, together with quercetin treatment, production of cytoprotective NO increases thereby protecting the tissues from I/R damage. (26). High concentrations of NO in the cardiac tissue may trigger preconditioning mechanism and decrease myocardial ischemia damage (27). Nitrite levels in our study indicated high levels of NO in the myocardial tissue treated with quercetin. This brings forward the pharmacological preconditioning inducing property that contributes to the cardioprotective effects of quercetin. Quercetin and other grape flavonoids increase endothelial NO levels and smooth muscle relaxation through the up-regulation of cyclic GMP and induce vasodilatation (28). This condition explains the high levels of coronary blood flow observed in groups receiving quercetin.

Both hemodynamic data and biochemical parameters pointed out to a better improvement with the use of chronic treatment protocol when compared to acute therapy protocol. This result might be due to effective concentrations of quercetin in the heart following seven days of administration. However, the improvement in the acute dose group was still better than those in control group.

Limitations of the study

The limitation of this study is that we have no opportunity to measure tissue levels of quercetin in the heart.


As a flavonoid that can be consumed in significant amounts in the daily diet; quercetin due to its antioxidant and cytoprotective effects, has the capacity to protect the myocardial tissue against global ischemia and reperfusion injury. In instances where the molecule is administered for the purpose of acute therapy, this significant cardioprotective effect can be observed; however, this potency is further accentuated upon administration as a chronic treatment protocol for seven days. Although we might speculate that the superiority of this chronic treatment protocol in our study was due to having effective tissue concentrations in the heart, we certainly need studies of larger scale to validate this argument.


(1.) Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res 1995; 22: 375-83.

(2.) de Vries JH, Hollman PC, Meyboom S, Buysman MN, Zock PL, van Staveren WA, et al. Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am J Clin Nutr 1998; 68: 60-5.

(3.) Hollman PC, Katan MB. Bioavailability and health effects of dietary flavonols in man. Arch Toxicol 1998; 20 Suppl: 237-48.

(4.) Guglielmone HA, Agnese AM, Montoya SC, Jose L. Cabrera. Anticoagulant effect and action mechanism of sulphated flavonoids from Flaveria bidentis. Thromb Res 2002; 105: 183-88.

(5.) Formica JV, Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995; 33: 1061-80.

(6.) Inal M, Altinisik M, Bilgin MD. The effect of quercetin on renal ischemia and reperfusion injury in the rat. Cell Biochem Funct 2002; 20: 291-6.

(7.) Dajas F, Rivera F, Blasina F, Arredondo F, Echeverry C, Lafon L, et al. Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox Res 2003; 5: 425-32.

(8.) Su JF, Guo CJ, Wei JY, Yang JJ, Jiang YG, Li YF. Protection against hepatic ischemia-reperfusion injury in rats by oral pretreatment with quercetin. Biomed Environ Sci 2003; 16: 1-8.

(9.) Kolchin IuN, Maksiutina NP, Balanda PP, Luik AI, Bulakh VN, Moibenko AA. The cardioprotective action of quercetin in experimental occlusion and reperfusion of the coronary artery in dogs. Farmakol Toksikol 1991 54: 20-3.

(10.) Floreani M, Napoli E, Quintieri L, Palatini P. Oral administration of transresveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci 2003; 72: 2741-50.

(11.) Asha S, Radha E. Effect of age and myocardial infarction on serum and heart lactic dehydrogenase. Exp Gerontol 1985; 20: 67-70.

(12.) Gerhardt W, Ljungdahl L, Herbert AK. Troponin T and CK-MB (mass) in early diagnosis of ischemic myocardial injury. Clin Biochem 1993; 26: 231-40.

(13.) Bertinchant JP, Larue C, Pernel I, Ledermann B, Fabbro-Peray P, Beck L, et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem 1996; 29: 587-94.

(14.) Beutler E. The glutathione instability of drug sensitive red cells; a new method for the in vitro detection of drug sensitivity. J Lab Clin Med 1957; 49: 84-95.

(15.) Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxidase in animal tissues by thiobarbituric acid reaction. Annal Biochem 1979; 95: 351-8.

(16.) Erden Inal M, Kahraman A, Koken T. Beneficial effects of quercetin on oxidative stress induced by ultraviolet A. Clin Exp Dermatol 2001 Sep; 26: 536-9.

(17.) Wang GF, Satake M, Horita K. Spectrophotometric determination of nitrate and nitrite in water and some fruit samples using column preconcentration. Talanta 1998; 46: 671-8.

(18.) Kaul N, Siveski-Iliskovic N, Hill M, Slezak J, Singal PK. Free radicals and the heart. J Pharmacol Toxicol Methods 1993; 30: 55-67.

(19.) Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart; evidence for a free radical mechanism of reperfusion injury. J Biol Chem 1988; 263: 1353-7.

(20.) Das DK, Engelmann RM, Rousou JA, Breyer RH, Otani H, Lemeshow S. Pathophysiology of superoxide radicals as potential mediator of reperfusion injury in pig heart. Basic Res Cardiol 1986; 81: 155-66.

(21.) Robicsek F, Schaper J. Reperfusion injury: fact or myth? J Cardiac Surg 1997; 12: 133-7.

(22.) Das DK, Maulik N. Antioxidant effectiveness in ischemia-reperfusion tissue injury. Methods Enzymol 1994; 233: 601-10.

(23.) Brookes PS, Digerness SB, Parks DA, Darley-Usmar V. Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin. Free Radic Biol Med 2002; 32: 1220-8.

(24.) Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341: 454-7.

(25.) Blardi P, De Lalla A, Volpi L, Di Perri T. Stimulation of Endogenous Adenosine Release by Oral Administration of Quercetin and Resveratrol in Man. Drugs Exp Clin Res 1999; 25: 105-10.

(26.) Huk I, Brovkovych V, Nanobash Vili J, Weigel G, Neumayer C, Partyka L, et al. Bioflavonoid quercetin scavenges superoxide and increases nitric oxide concentration in ischemia-reperfusion injury: an experimental study. Br J Surg 1998; 85: 1080-5.

(27.) Qiu Y, Rizvi A, Tand XL, Manchikalapudi S, Takano H, Jadoon AK, et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol 1997; 273: 2931-6.

(28.) Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol 1993; 265: 774-8.

Murat Ikizler, Nilufer Erkasap *, Sadettin Dernek, Tugrul Kural, Ziya Kaygisiz *

From Departments of Cardiovascular Surgery and Physiology *, Eskisehir Osmangazi University, Eskisehir, Turkey

Address for Correspondence/Yazisma Adresi: Dr. Murat Ikizler, Department of Cardiovascular Surgery Medicine Faculty of Eskisehir Osmangazi University 26020 Eskisehir, Turkey Phone: +90 222 239 78 28 Fax : +90 222 225 16 59 E-mail:

Note: This work was presented at 9th National Congress of Turkish Society of Cardiovascular Surgery, November 1-5, 2006, Antalya, Turkey
Table 1. Pre-ischemic and post-ischemic hemodynamic data and coronary
flow values

Periods of Group * Systolic
ischemia pressure
and reperfusion p **
 mm Hg value vs
 control control

 1 119.3 [+ or -] 5.7
Stabilization 2 120.2 [+ or -] 6.1 1.000
Period 3 118.3 [+ or -] 5.1 0.999
 4 111.7 [+ or -] 6.2 0.795

 1 70.1 [+ or -] 1.9
Reperfusion 2 80.4 [+ or -] 2.2 0.011
20. min 3 90.0 [+ or -] 2.4 0.001
 4 90.3 [+ or -] 2.1 0.001

 1 70.4 [+ or -] 1.6
Reperfusion 2 78.4 [+ or -] 1.8 0.029
40. min 3 87.0 [+ or -] 2.1 0.001
 4 86.9 [+ or -] 1.9 0.001

 1 9.6 [+ or -] 1.9
Reperfusion 2 79.0 [+ or -] 1.2 0.013
60. min 3 88.5 [+ or -] 2.0 0.001
 4 88.4 [+ or -] 2.6 0.001

Periods of Group * Diastolic
ischemia pressure
and reperfusion p **
 mmHg value vs

 1 12.6 [+ or -] 0.8
Stabilization 2 13.5 [+ or -] 0.4 0.860
Period 3 13.2 [+ or -] 0.8 0.953
 4 13.1 [+ or -] 0.9 0.972

 1 38.4 [+ or -] 1.4
Reperfusion 2 33.2 [+ or -] 1.3 0.013
20. min 3 27.9 [+ or -] 0.7 0.001
 4 28.6 [+ or -] 0.8 0.001

 1 38.0 [+ or -] 1.3
Reperfusion 2 33.4 [+ or -] 1.2 0.026
40. min 3 29.0 [+ or -] 0.7 0.001
 4 29.0 [+ or -] 0.9 0.001

 1 37.2 [+ or -] 0.9
Reperfusion 2 33.2 [+ or -] 0.9 0.030
60. min 3 29.3 [+ or -] 0.9 0.001
 4 29.2 [+ or -] 1.0 0.001

Periods of Group * +dP/dtmax
and reperfusion p **
 value vs

 1 4250 [+ or -] 22
Stabilization 2 3961 [+ or -] 25 0.826
Period 3 4247 [+ or -] 26 1.000
 4 4242 [+ or -] 20 1.000

 1 1030 [+ or -] 47
Reperfusion 2 1413 [+ or -] 67 0.018
20. min 3 1784 [+ or -] 92 0.001
 4 1767 [+ or -] 12 0.001

 1 1065 [+ or -] 36
Reperfusion 2 1470 [+ or -] 67 0.011
40. min 3 1845 [+ or -] 10 0.001
 4 1833 [+ or -] 10 0.001

 1 1050 [+ or -] 37
Reperfusion 2 1448 [+ or -] 91 0.011
60. min 3 1824 [+ or -] 10 0.001
 4 1787 [+ or -] 94 0.001

Periods of Group * Coronary flow
and reperfusion p **
 mL/min value vs

 1 18.1 [+ or -] 1.1
Stabilization 2 18.4 [+ or -] 0.7 0.976
Period 3 20.3 [+ or -] 1.1 0.882
 4 20.3 [+ or -] 1.1 0.939

 1 9.9 [+ or -] 0.4
Reperfusion 2 11.8 [+ or -] 0.4 0.033
20. min 3 13.9 [+ or -] 0.5 0.001
 4 13.8 [+ or -] 0.3 0.001

 1 10.2 [+ or -] 0.3
Reperfusion 2 11.9 [+ or -] 0.3 0.011
40. min 3 13.5 [+ or -] 0.3 0.001
 4 13.6 [+ or -] 0.4 0.001

 1 10.9 [+ or -] 0.3
Reperfusion 2 13.1 [+ or -] 0.5 0.024
60. min 3 15.3 [+ or -] 0.6 0.001
 4 15.5 [+ or -] 0.5 0.001

The values are expressed as the mean [+ or -] SEM

*-one way AN OVA analysis
**- post hoc Tukey multiple range test
Group 1 - control, Group 2 - acute treatment, Group 3 - chronic
treatment, Group 4- chronic and acute treatments

Table 2. Biochemical results

Variables Group * Period

 p** VS

 1 35.3 [+ or -] 6.9
LDH, IU/L 2 44.7 [+ or -] 6.4 0.999
 3 45.9 [+ or -] 8.0 0.978
 4 44.8 [+ or -] 8.2 0.938

 1 25.3 [+ or -] 1.6
CK-MB, 2 25.9 [+ or -] 2.1 0.983
1 U/L 3 24.3 [+ or -] 2.7 1.000
 4 21.1 [+ or -] 2.1 0.973

 1 0.85 [+ or -] 0.1
cTn I, 2 0.97 [+ or -] 0.1 0.895
mg/L 3 0.89 [+ or -] 0.1 0.994
 4 0.92 [+ or -] 0.1 0.958

MDA, 2
nmol/g pro 3

GSH, 2
nmol/g pro 3

GR, 2
nmol/min/ 3
mg pro 4

Nitrite, 2
mmol/g 3
tissue 4

Variables Group * Period

 p** VS

 1 278 [+ or -] 12
LDH, IU/L 2 238 [+ or -] 7 0.022
 3 201 [+ or -] 6 0.001
 4 199 [+ or -] 5 0.001

 1 128 [+ or -] 5.1
CK-MB, 2 103 [+ or -] 2.8 0.027
1 U/L 3 80.3 [+ or -] 5.6 0.004
 4 80.6 [+ or -] 8.5 0.001

 1 3.72 [+ or -] 0.1
cTn I, 2 2.95 [+ or -] 0.1 0.018
mg/L 3 2.10 [+ or -] 0.2 0.001
 4 2.17 [+ or -] 0.1 0.001

 1 120.1 [+ or -] 7.6
MDA, 2 99.66 [+ or -] 3.1 0.036
nmol/g pro 3 79.24 [+ or -] 3.2 0.001
 4 80.11 [+ or -] 4.1 0.001

 1 7.35 [+ or -] 0.2
GSH, 2 8.98 [+ or -] 0.7 0.011
nmol/g pro 3 10.52 [+ or -] 0.9 0.001
 4 10.53 [+ or -] 0.8 0.001

 1 16.0 [+ or -] 0.9
GR, 2 21.3 [+ or -] 1.3 0.017
nmol/min/ 3 25.8 [+ or -] 0.7 0.001
mg pro 4 26.1 [+ or -] 1.1 0.001

 1 122.69 [+ or -] 21
Nitrite, 2 278.27 [+ or -] 31 0.001
mmol/g 3 426.50 [+ or -] 38 0.001
tissue 4 433.63 [+ or -] 40 0.001

The values are expressed as the mean [+ or -] SEM

*-one way AN OVA analysis

**- post hoc Tukey multiple range test

Group 1- control, Group 2- acute treatment, Group 3- chronic treatment,
Group 4 chronic and acute treatments

CK-MB- creatine kinase activity, cTn I- cardiac troponin I,
GSH- glutathione, GR- glutathione reductase, LOW lactate
dehydrogenase, MDA- malondialdehyde
COPYRIGHT 2007 Galenos Yayincilik
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Investigation / Orijinal Arastirma
Author:Ikizler, Murat; Erkasap, Nilufer; Dernek, Sadettin; Kural, Tugrul; Kaygisiz, Ziya
Publication:The Anatolian Journal of Cardiology (Anadolu Kardiyoloji Dergisi)
Article Type:Clinical report
Geographic Code:7TURK
Date:Dec 1, 2007
Previous Article:Evaluation of hemodynamic changes in patients with mitral valve replacement using dobutamine stress echocardiography / Mitral kapak replasmani...
Next Article:Does cardiopulmonary bypass change serum neuron-specific enolase levels? / Kardiyopulmoner baypas serum noron spesifik enolaz duzeyini degistiriyor...

Related Articles
Miyokardiyal iskemi-reperfuzyon hasari ve melatonin/Myocardial ischemia-reperfusion injury and melatonin.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters